ATYR LAWSUIT ALERT: Levi & Korsinsky Notifies aTyr Pharma, Inc. Investors - Lead Plaintiff Deadline December 8, 2025

New York, New York--(Newsfile Corp. - October 9, 2025) - If you suffered a loss on your aTyr Pharma, Inc. (NASDAQ: ATYR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:

https://zlk.com/pslra-1/atyr-pharma-inc-lawsuit-submission-form?prid=171533&wire=5&utm_campaign=7

or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.

THE LAWSUIT: A class action securities lawsuit was filed against aTyr Pharma, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between January 16, 2025 and September 12, 2025.

CASE DETAILS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning the efficacy of Efzofitimod, particularly, the drug's capability to allow a patient to completely taper their steroid usage.

The truth emerged on September 15, 2025 (pre-market) when aTyr hosted an investor call announcing that the EFZO-FIT study did not meet its primary endpoint. In pertinent part, defendants announced that the study did not meet the primary endpoint in change from baseline in mean daily OSC dose at week 48. Additionally, aTyr announced that the Company's next step was to engage with the FDA to determine a path forward, given the disappointing topline results.

Following this news, the price of aTyr's common stock declined from a closing market price of $6.03 per share on September 12, 2025 to $1.02 per share on September 15, 2025, a decline of 83.2% in the span of just a single day.

WHAT'S NEXT? If you suffered a loss in aTyr stock during the relevant time frame - even if you still hold your shares - go to https://zlk.com/pslra-1/atyr-pharma-inc-lawsuit-submission-form?prid=171533&wire=5&utm_campaign=7 to learn about your rights to seek a recovery. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/269904